JP7362596B2 - 免疫療法のためのｐｄｅ５組成物及び方法 - Google Patents

免疫療法のためのｐｄｅ５組成物及び方法 Download PDF

Info

Publication number
JP7362596B2
JP7362596B2 JP2020517774A JP2020517774A JP7362596B2 JP 7362596 B2 JP7362596 B2 JP 7362596B2 JP 2020517774 A JP2020517774 A JP 2020517774A JP 2020517774 A JP2020517774 A JP 2020517774A JP 7362596 B2 JP7362596 B2 JP 7362596B2
Authority
JP
Japan
Prior art keywords
cell
domain
seq
polypeptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020517774A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525536A (ja
JP2020525536A5 (enExample
Inventor
ヴィピン スリ，
バイロン デラバール，
マイケル エヌ． グラッドストーン，
セレステ リチャードソン，
ブライアン ドリンスキ，
アビシェク クルカルニ，
マラ クリスティーン イニス，
デシュエ スン，
ダン ジュン リー，
グレース ワイ． オリンガー，
スコット フランシス ヘラー，
Original Assignee
オブシディアン セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オブシディアン セラピューティクス， インコーポレイテッド filed Critical オブシディアン セラピューティクス， インコーポレイテッド
Publication of JP2020525536A publication Critical patent/JP2020525536A/ja
Publication of JP2020525536A5 publication Critical patent/JP2020525536A5/ja
Priority to JP2023133318A priority Critical patent/JP2023144094A/ja
Application granted granted Critical
Publication of JP7362596B2 publication Critical patent/JP7362596B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04035—3',5'-Cyclic-GMP phosphodiesterase (3.1.4.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020517774A 2017-06-12 2018-06-12 免疫療法のためのｐｄｅ５組成物及び方法 Active JP7362596B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023133318A JP2023144094A (ja) 2017-06-12 2023-08-18 免疫療法のためのｐｄｅ５組成物及び方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762518078P 2017-06-12 2017-06-12
US62/518,078 2017-06-12
US201762523850P 2017-06-23 2017-06-23
US201762523862P 2017-06-23 2017-06-23
US62/523,862 2017-06-23
US62/523,850 2017-06-23
US201762555313P 2017-09-07 2017-09-07
US62/555,313 2017-09-07
PCT/US2018/037005 WO2018231759A1 (en) 2017-06-12 2018-06-12 Pde5 compositions and methods for immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023133318A Division JP2023144094A (ja) 2017-06-12 2023-08-18 免疫療法のためのｐｄｅ５組成物及び方法

Publications (3)

Publication Number Publication Date
JP2020525536A JP2020525536A (ja) 2020-08-27
JP2020525536A5 JP2020525536A5 (enExample) 2021-07-26
JP7362596B2 true JP7362596B2 (ja) 2023-10-17

Family

ID=64660633

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020517774A Active JP7362596B2 (ja) 2017-06-12 2018-06-12 免疫療法のためのｐｄｅ５組成物及び方法
JP2023133318A Pending JP2023144094A (ja) 2017-06-12 2023-08-18 免疫療法のためのｐｄｅ５組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023133318A Pending JP2023144094A (ja) 2017-06-12 2023-08-18 免疫療法のためのｐｄｅ５組成物及び方法

Country Status (9)

Country Link
US (2) US11241485B2 (enExample)
EP (1) EP3638289A4 (enExample)
JP (2) JP7362596B2 (enExample)
CN (1) CN111107866A (enExample)
CA (1) CA3067211A1 (enExample)
MA (1) MA49403A (enExample)
MX (1) MX2019014960A (enExample)
SG (1) SG11201912010XA (enExample)
WO (1) WO2018231759A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US11253546B2 (en) * 2014-12-15 2022-02-22 The Regents Of The University Of California Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
AU2018227583B2 (en) * 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
AU2018273796A1 (en) * 2017-05-23 2020-01-16 Biovite Australia Pty Ltd Extracts from Arthrospira and uses thereof
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
MA49403A (fr) 2017-06-12 2021-03-24 Obsidian Therapeutics Inc Compositions de pde5 et méthodes d'immunothérapie
WO2018237323A1 (en) * 2017-06-23 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Pde5a destabilizing domains
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
CA3098128A1 (en) 2018-04-18 2019-10-24 Ucl Business Ltd Engineered regulatory t cell
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3813878A4 (en) 2018-06-14 2022-03-16 2seventy bio, Inc. CAR ANTI-BCMA ANTIBODIES, CONJUGATES AND METHODS OF USE
AU2019372673A1 (en) 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
WO2020123716A1 (en) * 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
EP3912992A4 (en) 2019-02-04 2022-11-23 National University Corporation Ehime University Car library and production method for scfv
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
CA3132817A1 (en) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Cd40l compositions and methods for tunable regulation
WO2020210665A1 (en) * 2019-04-12 2020-10-15 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors with cd20 safety switch
JP7675016B2 (ja) * 2019-05-08 2025-05-12 メモリアル スローン ケタリング キャンサー センター ムチン－１６に対するヒト化抗体およびそれを使用する方法
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. MADCAM TARGETED IMMUNOTLERANCE
EP3976659A4 (en) * 2019-05-24 2023-02-22 Memorial Sloan Kettering Cancer Center Anti-glypican-3 antibodies and uses thereof
WO2021034952A1 (en) * 2019-08-19 2021-02-25 Elpis Biopharmaceuticals Anti-cd19 antibodies and uses thereof
CN114765980A (zh) * 2019-09-06 2022-07-19 加利福尼亚大学董事会 用于治疗癌症的嵌合抗原受体及相关方法和组合物
WO2021050789A1 (en) * 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
JP7744335B2 (ja) * 2019-10-11 2025-09-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヒトサイトメガロウイルスに対するキメラ抗原受容体
CA3161573A1 (en) * 2019-12-12 2021-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for cd276 and uses thereof
US20230030085A1 (en) * 2019-12-16 2023-02-02 2Seventy Bio, Inc. Anti-bcma car antibodies, conjugates, and methods of use
AU2020407235A1 (en) * 2019-12-20 2022-07-07 Poseida Therapeutics, Inc. Anti-MUC1 compositions and methods of use
KR20220139319A (ko) 2020-01-08 2022-10-14 옵시디안 테라퓨틱스, 인크. 조정 가능한 전사의 조절을 위한 조성물 및 방법
WO2021167723A1 (en) * 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Chimeric scavenger receptors targeted to phosphorylated tau (ptau) and uses thereof
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
WO2021175250A1 (en) * 2020-03-03 2021-09-10 Aptorum Therapeutics Limited Compounds and methods for treating diseases and/or conditions caused by coronavirus
WO2021202941A1 (en) * 2020-04-03 2021-10-07 University Of Cincinnati Secreted phosphorylated heat shock protein-70 as a biomarker for treating and diagnosing cancer
WO2021216686A1 (en) * 2020-04-21 2021-10-28 Arizona Board Of Regents On Behalf Of Arizona State University Treating and curing covid-19 infection utilizing a laser
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
US12012458B2 (en) * 2020-06-12 2024-06-18 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
EP4168053A1 (en) 2020-06-22 2023-04-26 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of cas nucleases
WO2022006588A1 (en) * 2020-06-29 2022-01-06 Trustees Of Tufts College Il-38 and analogues thereof for treatment of neuro-inflammatory and neurodegenerative diseases
US11508453B2 (en) * 2020-08-18 2022-11-22 Micron Technology, Inc. Encoding test data of microelectronic devices, and related methods, devices, and systems
GB202013477D0 (en) * 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells
CN114516914B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN116981697A (zh) * 2021-01-14 2023-10-31 森迪生物科学公司 可分泌有效载荷调节
AU2022211438A1 (en) 2021-01-19 2023-08-17 Obsidian Therapeutics, Inc. Tumor-infiltrating lymphocytes with membrane bound interleukin 15 and uses thereof
WO2022187710A1 (en) 2021-03-05 2022-09-09 Atreca, Inc. Epha2 antibodies
US20240218069A1 (en) * 2021-04-28 2024-07-04 Lyvgen Biopharma Holdings Limited Bi-specific antibodies comprising anti-b7h3 binding molecules
CA3218215A1 (en) * 2021-05-19 2022-11-24 Biliang HU Bi-specific chimeric antigen receptors and genetically engineered immune cells expressing such
EP4372089A4 (en) * 2021-07-16 2025-07-09 Noile Immune Biotech Inc CHIMERIC ANTIGEN RECEPTOR, CELL EXPRESSING SAID RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR CONTAINING A BASE SEQUENCE ENCODING SAID CHIMERIC ANTIGEN RECEPTOR
CN113564184B (zh) * 2021-07-16 2023-04-18 昆明理工大学 一种天麻谷氨酰胺合成酶基因及其应用
IL309914A (en) 2021-07-29 2024-03-01 Takeda Pharmaceuticals Co Immune cells express a chimeric antigen receptor that specifically targets mesothelin and their uses
CA3233380A1 (en) 2021-10-18 2023-04-27 Dhruv SETHI Compositions and systems for regulation of function/abundance and delivery of polypeptide payloads
US20250134928A1 (en) 2022-01-18 2025-05-01 Obsidian Therapeutics, Inc. Methods for identifying and using allogeneic tumor infiltrating lymphocytes to treat cancer
CN114606323B (zh) * 2022-04-24 2023-11-10 深圳大学 一种识别胃癌干细胞的标志物lgsn作为胃癌诊断和治疗靶标的应用
JP2025516189A (ja) * 2022-04-28 2025-05-27 イマティクス ユーエス，アイエヌシー． 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法
CN116063507A (zh) * 2022-05-11 2023-05-05 迈威(上海)生物科技股份有限公司 抗人gas6抗体或其抗原结合片段及其应用
WO2024011104A1 (en) 2022-07-05 2024-01-11 Neomics Pharmaceuticals Llc Chimeric antigen receptor comprising bcma nanobody linked to a chimeric intracellular signaling domain
EP4374872A1 (en) * 2022-11-22 2024-05-29 Koninklijke Philips N.V. Pde enhanced car-t cells
CN117482245B (zh) * 2022-12-30 2024-10-29 英百瑞(杭州)生物医药有限公司 抗5t4抗体-自然杀伤细胞偶联物及其用途
WO2024165024A1 (zh) * 2023-02-09 2024-08-15 星尘生物科技(上海)有限公司 一种嵌合抗原受体及其应用
CN116004547B (zh) * 2023-03-06 2025-04-25 浙江康佰裕生物科技有限公司 一种辐照car-t细胞及其制备方法与应用
EP4474016A1 (en) 2023-06-07 2024-12-11 Julius-Maximilians-Universität Würzburg Strategies to target extracellularly accessible ras protein
WO2025049981A1 (en) * 2023-09-01 2025-03-06 Institute For Environmental Health, Inc. Variably deamidated gluten polypeptides and antibodies against same
WO2025051339A1 (en) * 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
WO2025072355A1 (en) * 2023-09-25 2025-04-03 Biohybrid Solutions Holdings, Inc. Methods for and compositions of non-peg bioconjugates with ultra-high drug-to-agent ratio
WO2025122943A1 (en) 2023-12-08 2025-06-12 Obsidian Therapeutics, Inc. Compositions and methods for enhanced payload regulation using nuclear factor of activated t cells (nfat) response elements
WO2025144887A1 (en) 2023-12-27 2025-07-03 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of il15 and light
CN119930817B (zh) * 2024-12-24 2025-12-02 国科大杭州高等研究院 Tigit全人源抗体及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215169A1 (en) 2007-02-09 2009-08-27 Wandless Thomas J Method for regulating protein function in cells using synthetic small molecules
US20140010791A1 (en) 2008-05-07 2014-01-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for regulating protein function in cells in vivo using synthetic small molecules
US20160202256A1 (en) 2015-01-12 2016-07-14 President And Fellows Of Harvard College Biosensors Engineered from Conditionally Stable Ligand-Binding Domains
US20170157176A1 (en) 2015-12-08 2017-06-08 Chimera Bioengineering, Inc. Smart CAR Devices and DE CAR Polypeptides for Treating Disease and Methods for Enhancing Immune Responses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023091A2 (en) * 1998-10-15 2000-04-27 Bioimage A/S Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
WO2003054150A2 (en) 2001-12-07 2003-07-03 The Ohio State University Research Foundation Apoptotic ebv-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
US20090087871A1 (en) 2004-05-28 2009-04-02 Atlanta Pharma Ag Method for Identifying PDE5-Modulators
WO2007142929A2 (en) 2006-05-31 2007-12-13 The University Of North Carolina At Chapel Hill Novel pde4 inhibitors
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
CA3133545C (en) * 2012-05-25 2023-08-08 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
US20140255361A1 (en) * 2013-03-07 2014-09-11 The Board Of Trustees Of The Leland Stanford Junior University Estrogen-receptor based ligand system for regulating protein stability
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US20170291934A1 (en) 2014-09-22 2017-10-12 Charles C. Reed Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
US11655452B2 (en) 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
EP3331905B1 (en) * 2015-08-06 2022-10-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3464375A2 (en) 2016-06-02 2019-04-10 Novartis AG Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
AU2018227583B2 (en) 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
JP7660343B2 (ja) 2017-03-03 2025-04-11 オブシディアン セラピューティクス， インコーポレイテッド 免疫療法のための組成物及び方法
WO2018161026A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
WO2018161038A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il12 compositions and methods for immunotherapy
MA49403A (fr) 2017-06-12 2021-03-24 Obsidian Therapeutics Inc Compositions de pde5 et méthodes d'immunothérapie
WO2018237323A1 (en) * 2017-06-23 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Pde5a destabilizing domains

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215169A1 (en) 2007-02-09 2009-08-27 Wandless Thomas J Method for regulating protein function in cells using synthetic small molecules
US20140010791A1 (en) 2008-05-07 2014-01-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for regulating protein function in cells in vivo using synthetic small molecules
US20160202256A1 (en) 2015-01-12 2016-07-14 President And Fellows Of Harvard College Biosensors Engineered from Conditionally Stable Ligand-Binding Domains
US20170157176A1 (en) 2015-12-08 2017-06-08 Chimera Bioengineering, Inc. Smart CAR Devices and DE CAR Polypeptides for Treating Disease and Methods for Enhancing Immune Responses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Alexandre Juillerat, et al.，Design of chimeric antigen receptors with integrated controllable transient functions，Scientific Reports，2016年01月11日，6:18950，pp.1-7，DOI: 10.1038/srep18950

Also Published As

Publication number Publication date
JP2020525536A (ja) 2020-08-27
CN111107866A (zh) 2020-05-05
SG11201912010XA (en) 2020-01-30
EP3638289A1 (en) 2020-04-22
WO2018231759A1 (en) 2018-12-20
US11666642B2 (en) 2023-06-06
CA3067211A1 (en) 2018-12-20
US20200101142A1 (en) 2020-04-02
EP3638289A4 (en) 2021-03-24
US11241485B2 (en) 2022-02-08
US20230074330A1 (en) 2023-03-09
MA49403A (fr) 2021-03-24
MX2019014960A (es) 2020-08-06
JP2023144094A (ja) 2023-10-06

Similar Documents

Publication Publication Date Title
JP7362596B2 (ja) 免疫療法のためのｐｄｅ５組成物及び方法
US12104178B2 (en) DHFR tunable protein regulation
EP3806888B1 (en) Pde5 derived regulatory constructs and methods of use in immunotherapy
US20230250179A1 (en) Bcma chimeric antigen receptors and uses thereof
JP7341900B2 (ja) 免疫療法のためのｃｄ１９組成物及び方法
JP7620560B2 (ja) 調整可能な制御のためのヒトカルボニックアンヒドラーゼ２組成物及び方法
US20210386788A1 (en) Er tunable protein regulation
CN106687483A (zh) 使用人源化抗‑bcma嵌合抗原受体治疗癌症
JPWO2019241426A5 (enExample)
CN107109419A (zh) 使用cd33嵌合抗原受体治疗癌症
WO2018161000A1 (en) Dhfr tunable protein regulation
JP2025185029A (ja) 免疫療法のためのｃｄ１９組成物及び方法
TW202307210A (zh) Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
HK40029493A (en) Pde5 compositions and methods for immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230911

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231004

R150 Certificate of patent or registration of utility model

Ref document number: 7362596

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150